earnings
Obesity Trials Widen Net Loss: Massive Cash Reserves Secure Runway (VKTX Q4 2025 Earnings Call)
Viking Therapeutics reported widening net losses for both the fourth quarter and the full year as the company accelerated its obesity pipeline into late-stage clinical trials. This operational expansion represents a crucial turning point, positioning the biotechnology firm to potentially deliver the industry's first oral and subcutaneous dual-agonist weight loss platform.